Clinical and epidemiologic burden of chronic myelogenous leukemia

Expert Review of Anticancer Therapy

Volumn 4, Issue 1, 2004, Pages 85-96

  Redaelli, Alberto ^a   Bell, Christopher F ^b   Casagrande, Jodie ^b   Stephens, Jennifer M ^b   Botteman, Marc F ^b   Laskin, Benjamin L ^b   Pashos, Chris L ^c  

^a Pharmacia Corporation   (Italy)

^b HERQuLES   (United States)

^c HERQuLES   (United States)

Author keywords

Bone marrow transplantation; Chemotherapy; Chronic myelogenous leukemia; Diagnosis; Epidemiology

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BUSULFAN; CORTICOSTEROID; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOSPORIN; CYTARABINE; HEAT SHOCK PROTEIN 90; HYDROXYUREA; IMATINIB; METHOTREXATE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ALOPECIA; ANOREXIA; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOPENIA; DEPRESSION; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEADACHE; HEART MUSCLE FIBROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; HYPOTENSION; HYPOTHYROIDISM; LIVER FIBROSIS; LUNG FIBROSIS; MALE; MORBIDITY; MYALGIA; NEPHRITIS; PARESTHESIA; PHILADELPHIA 1 CHROMOSOME; PREVALENCE; RADIATION EXPOSURE; REVIEW; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOCYTOPENIA; WEIGHT REDUCTION; WHOLE BODY RADIATION;

EID: 1142287358     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.1.85     Document Type: Review

References (49)

1. Goldman J. ABC of clinical haematology. Chronic myeloid leukaemia. Br. Med. J 314(7081), 657-660 (1997).
2. Rector JT, Veillon DM, Schumacher HR, Cotelingam JD. The chronic leukemias of myeloid origin. Med. Lab. Observer 30(12), 28 (1998).
3. Sawyers CL. Chronic myeloid leukemia. N. Engl. J .Med. 340(17), 1330-1340 (1999).
4. Deisseroth AB, Kantarjian HM, Andreeff M et al. Cancer: Principles and Practice of Oncology, 5th edition. Lippincott Williams & Wilkins, PA, USA (1997).
5. Faderl S, Kantarjian HM, Talpaz M, O'Brien S. New treatment approaches for chronic myelogenous leukemia. Semin. Oncol. 27(5), 578-586 (2000).
6. McGuire TR, Kazakoff PW. Pharmacotherapy: A Pathophysiologic Approach, 4th edition. Elsevier, NY, USA (1999).
7. Parkin DM, Whelan SL, Feraly J, Raymond L, Young J. Cancer Incidence in Five Continents, Volume VII. IARC Scientific Publication number 143, Lyon, France (1997).
8. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute, MD, USA (2002).
9. Faded S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341(3), 164-172 (1999).
10. Lee SJ. Chronic myelogenous leukaemia. Br. J. Haematol. 111(4), 993-1009 (2000).
11. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5), 1517-1536 (1999).
12. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131(3), 207-219 (1999).
13. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 1998. AIHW Canberra, Australia (2001).
14. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352(9134), 1087-1092 (1998).
15. Pigneux A, Tanguy ML, Michallet M et al. Prior treatment with α-interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br. J. Haematol. 116(1), 193-201 (2002).
16. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001).
17. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344(14), 1038-1042 (2001).
18. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology (Am. Soc. Hematol. Educ. Program) 87-112 (2001).
19. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99(6), 1928-1937 (2002).
20. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-α and chemotherapy. Hematol. Oncol. Clin. North Am. 12(1), 31-80 (1998).
21. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17(Suppl. 3), S5-S6 (1996).
22. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 6(1), 34-55 (2001).
23. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 63(4), 789-799 (1984).
24. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 82(2), 398-407 (1993).
25. 2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72(2), 642-647 (1988).
26. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-α in chronic myelogenous leukemia. N. Engl. J. Med. 314(17), 1065-1069 (1986).
27. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human α-interferon in chronic myelogenous leukemia. Blood 69(5), 1280-1288 (1987).
28. 2b for chronic myeloid leukemia. The Benelux CML Study Group. Blood 91(8), 2713-2721 (1998).
29. Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86(3), 906-916 (1995).
30. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345(8962), 1392-1397 (1995).
31. 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. N. Engl. J. Med. 330(12), 820-825 (1994).
32. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84(12), 4064-4077 (1994).
33. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon-α versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Chronic Myeloid Leukemia Trialists' Collaborative Group. J. Natl Cancer Inst. 89(21), 1616-1620 (1997).
34. 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N. Engl. J. Med. 337(4), 223-229 (1997).
35. Mahon FX, Montastruc M, Faberes C, Reiffers J. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon-α. Blood 84(10), 3592-3594 (1994).
36. McGlave P. The first 1000 unrelated donor transplants for chronic myeloid leukemia: lessons from the National Marrow Donor Program (NMDP) experience. Blood 88(Suppl. 1), 483a (1996).
37. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 9(4), 269-275 (1992).
38. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions; in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86(5), 2041-2050 (1995).
39. Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 82(10), 3211-3219 (1993).
40. Andrykowski MA, Greiner CB, Altmaier EM et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br. J. Cancer 71(6), 1322-1329 (1995).
41. Kantarjian HM, Talpaz A Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol. 28(5 Suppl. 17), 9-18 (2001).
42. Druker BJ. Current treatment approaches for chronic myelogenous leukemia. Cancer J. 7(Suppl. 1), S14-S18 (2001).
43. Belec RH. Quality of life: perceptions of long-term survivors of bone marrow transplantation. Oncol. Nurs. Forum 19(1), 31-37 (1992).
44. Haberman M, Bush N, Young K, Sullivan KM. Quality of life of adult long-term survivors of bone marrow transplantation: a qualitative analysis of narrative data. Oncol. Nurs. Forum 20(10), 1545-1553 (1993).
45. Carella AM, Frassoni F, Melo J et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 82(4), 478-495 (1997).
46. van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20, 553-560 (1977).
47. Clift RA, Anasetti C. Allografting for chronic myeloid leukemia. Baillieres Clin. Haematol. 10, 319-336 (1997).
48. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 81, 543-550 (1993).
49. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants fron unrelated donors for patients with chronic myeloid leukemia. N. Engl. J. Med. 338, 962-968 (1998).